Optimal design of clinical trials with computer simulation based on results of earlier trials, illustrated with a lipodystrophy trial in HIV patients

The designer of a clinical trial needs to make many assumptions about real-life practice based on prior knowledge. Simulation allows us to learn from experience by using the information obtained from a trial to improve the original estimators of population parameters. We propose using data from a previous trial to formulate assumptions that can be used to simulate trials and thus improve the design of new trials. To demonstrate our method, we used data from a real clinical trial which had been designed to evaluate cholesterol level changes as a surrogate marker for lipodystrophy in HIV patients. We were able to identify the optimal design that would have minimised the cost of a trial subject to a statistical power constraint which could then be used to design a new trial. In particular, we focused on three factors: the distribution of cholesterol levels in HIV patients, trial recruitment rates and trial dropout rates. We were able to verify our hypothesis that the total cost resulting from carrying out a clinical trial can be minimised by applying simulation models as an alternative to conventional approaches. In our findings the simulation model proved to be very intuitive and a useful method for testing the performance of investigators' assumptions and generating an optimal clinical trial design before being put into practice in the real world. In addition, we concluded that simulation models provide a more accurate determination of power than conventional approaches, thus minimising the total cost of clinical trials.

[1]  R. Paredes,et al.  Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  D. Warner,et al.  Statistical power, sample size, and their reporting in randomized controlled trials , 1995 .

[3]  Yasuo Ohashi,et al.  Statistical comparison of random allocation methods in cancer clinical trials. , 2004, Controlled clinical trials.

[4]  B. Clotet,et al.  Cumulative risk for developing hyperlipidemia in HIV-infected patients treated with protease inhibitors , 1999 .

[5]  Douglas G Altman,et al.  Treatment allocation by minimisation , 2005, BMJ : British Medical Journal.

[6]  Wayne Ewy,et al.  Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease , 2006, Pharmaceutical Research.

[7]  K. Carroll,et al.  Optimizing randomized phase II trials assessing tumor progression. , 2007, Contemporary clinical trials.

[8]  Josep Casanovas,et al.  Validation by simulation of a clinical trial model using the standardized mean and variance criteria , 2006, J. Biomed. Informatics.

[9]  A. Kirby,et al.  Sample size estimation using repeated measurements on biomarkers as outcomes. , 1994, Controlled clinical trials.

[10]  E. Eisenhauer,et al.  Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J M Lachin,et al.  Statistical considerations in the intent-to-treat principle. , 2000, Controlled clinical trials.

[12]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[13]  Scott Tonidandel,et al.  Sample size and power calculations in repeated measurement analysis , 2001, Comput. Methods Programs Biomed..

[14]  R. Kronmal,et al.  Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial setting. , 2005, Contemporary clinical trials.